Why is Oxford Nanopore Technologies stock up 7% today?

Onterris Inc. (NYSE:ONT) reported Q2 revenue of $186.7M, down from $234.5M YoY, and cut 2026 guidance. EBITDA margin improved to 17.1%. The company initiated a strategic review and adopted a poison pill. Net income fell to $1.4M, and operating cash flow turned negative. Hedge fund ownership declined, while short interest rose to 10.22%.

Oxford Nanopore Technologies' shares fell 6.5% to 162.08p after Novo Holdings sold 49 million shares at a 12.3% discount. This follows mixed reactions to the company's H1 2026 results, showing revenue growth but geographic weaknesses. The UK's FTSE 100 also declined due to Middle East tensions and rising bond yields, impacting growth stocks like Oxford Nanopore.

Merck (MRK) and Moderna (MRNA) announced positive Phase III results for their cancer vaccine, intismeran, showing improved outcomes when combined with Keytruda. Shares of both companies surged, with Moderna gaining 130.5% over three days. Sequencing companies like Illumina (ILMN) and PacBio (PACB) also saw gains due to the personalized nature of the therapy. Analysts upgraded Moderna's stock, citing broadened sales potential, while others remained cautious about long-term expectations.

Oxford Nanopore Technologies' stock rose 6.6% after its interim results showed improved profitability, with gross margin expanding to 62.2% and adjusted EBITDA losses halving. The company also announced a new licensing deal expected to generate $20 million in fees. Berenberg maintained a Buy rating but lowered its price target to £2.00. The stock is still below its 52-week high of 215.6p.

Bank of America downgraded Onterris, Inc. to Underperform from Neutral and cut its price target to $18 from $31, according to the note cited in the article. The stock is shown trading around $15.24 at the time of publication, with the article referencing Onterris’ recent earnings call.

Onterris (NYSE:ONT) reported Q2 CY2026 revenue of $186.7 million, down 20.4% year on year, missing analysts’ estimates. The company’s full-year revenue guidance midpoint was $765 million, 10.9% below consensus. Non-GAAP EPS was $0.51, above estimates, and the stock fell 17.5% to $18.73 after results.